Abstract 586P
Background
Although ctDNA is associated with MRD and recurrence in curatively treated CRC, implementation in clinical practice remains to be optimised. We evaluated the utility of a tumour naive ctDNA assay using serial prospectively collected plasma samples from the ASpirin for Dukes C and high risk Dukes B COLorecTal cancer trial (ASCOLT, NCT00565708), a large randomised phase III study of adjuvant aspirin.
Methods
Plasma samples were collected at baseline, 6 and 12 m in the Australian/ New Zealand cohort (n= 452). In a cohort of 118 pts matched by follow-up time (59 with recurrence [cases] and 59 non-recurrent [controls]), we used an ultra-sensitive ctDNA assay (SafeSEQ, Sysmex Inostics) for MRD detection. Cell pellets were analysed for mutations related to clonal haematopoiesis of indeterminate potential (CHIP). Results were correlated with recurrence and CEA.
Results
291 plasma samples (median 4.0 mL, median DNA 71.0 gen equiv/uL) were analysed (54/118 F; median age 68; 48 high risk stage II, 70 stage III; all had adjuvant chemotherapy; median follow-up 53.1 m). 59 pts recurred at median 12.4 m, of whom 32 had detectable ctDNA (sens 54%, Table). CEA sensitivity for detecting recurrence was 26%. Of the 27 pts with recurrence but no detectable ctDNA, 13 (48%) recurred >12 m after final sample collection. 8 pts without recorded recurrence had plasma mutations (CHIP analysis not available n = 3, all TP53). In multivariate analysis adjusting for known risk factors, ctDNA positivity was independently associated with recurrence (OR, 6.5; 95% CI, 2.2 – 18.9; p<0.001). Median time from 1st positive ctDNA to imaging detected recurrence was 7.9 m (range 0.2 – 40.2). ctDNA change over time and correlation with tumour sequencing will be presented. Table: 586P
Summary of ctDNA Data
Recurrence | No recurrence | Total | |
Positive ctDNA* at any time point | 32 | 8 | 40 |
Negative ctDNA | 27 | 51 | 78 |
Total | 59 | 59 | |
Sensitivity 54% | Specificity 86% |
*SafeSEQ 14 gene CRC MRD assay: AKT1, APC, BRAF, CTNNB1, ERBB3, FBXW7, KRAS, NRAS, PIK3CA, POLE, PPP2R1A, RNF43, SMAD4 and TP53
Conclusions
Tumour naïve, serial ctDNA detection within 1 year of adjuvant chemotherapy is independently associated with recurrence, noting limitations in sensitivity and specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Australasian Gastro-Intestinal Cancer Trials Group and Royal Australasian College of Physicians Foundation.
Disclosure
A. Starus: Non-Financial Interests, Institutional, Member, Anna Starus is an employee of Sysmex Inostics, Inc: Sysmex Inostics. F.S. Jones: Non-Financial Interests, Institutional, Member, Frederick Jones is an employee of Sysmex Inostics, Inc.: Sysmex Inostics. All other authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10